Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cyclophosphamide 8pembrolizumab 7fludarabine 6aldesleukin 4Papillomavirus Vaccines 4Vaccines 3Radiotherapy 3Light Coagulation 3Biopsy 3spartalizumab 2fludarabine phosphate 2entinostat 2Watchful Waiting 2Vorinostat 2VGX-3100 2Trastuzumab 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Paclitaxel 2Observation 2Nivolumab 2Interleukin-2 2Interleukin-12 Subunit p35 2Early Intervention, Educational 2Drug Therapy 2Carboplatin 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × MEDI0457 × Gynecologic × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡